Dennis Podlesak

Selected news for the person - Dennis Podlesak, collected since 5/2019. Recent stories appear in thelincolnianonline.com and rivertonroll.com. We are still establishing healthcare news links for this person.

Please provide a valid email address.
Shares Healthcare News With (link):
Other Healthcare Entities

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/24/2021 Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Analyst Downgrade thelincolnianonline.com ... given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $27.58. Get Syndax Pharmaceuticals alerts:In related news, Director Dennis Podlesak acquired 13,967 shares of Syndax Pharmaceuticals stock in a transaction dated Thursday, April 22nd. The shares were purchased at an average cost of $14.11 per share, with a total value of $197,074.37. Following the ...
4/24/2021 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Acquires $197,074.37 in Stock rivertonroll.com Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Acquires $197,074.37 in Stock Posted by Lars CharterSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak bought 13,967 shares of the company’s stock in a transaction that occurred on Thursday, April 22nd. The shares were purchased at an average price of $14.11 per share, with a total value of $197,074.37. Following the transaction, the director now directly owns 43,300 shares in the company ...
4/24/2021 Dennis Podlesak Acquires 13,967 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Mayfield Recorder Dennis Podlesak Acquires 13,967 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Posted by Frank Smitson on Apr 24th, 2021Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak purchased 13,967 shares of the firm’s stock in a transaction that occurred on Thursday, April 22nd. The shares were bought at an average price of $14.11 per share, with a total value of $197,074.37. Following the acquisition, the director now directly ...
4/23/2021 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 Shares - American Banking News American Banking News Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 SharesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak bought 13,967 shares of Syndax Pharmaceuticals stock in a transaction dated Thursday, April 22nd. The shares were bought at an average cost of $14.11 per share, with a total value of $197,074.37. Following the completion of the acquisition, the director now owns 43,300 shares of the company’s stock, valued at ...
4/23/2021 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Purchases $197,074.37 in Stock | Daily Political Daily Political ... GBX 1 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Purchases $197,074.37 in Stock Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Purchases $197,074.37 in Stock - Filed Under - by Jeff Wilder TweetSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak acquired 13,967 shares of the business’s stock in a transaction on Thursday, April 22nd. The stock was acquired at an average price of $14.11 per share, with a total value of $197,074.37. Following ...
4/23/2021 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 Shares zolmax.com Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 Shares Posted by John Perry on Apr 22nd, 2021 TweetSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak bought 13,967 shares of Syndax Pharmaceuticals stock in a transaction dated Thursday, April 22nd. The shares were bought at an average cost of $14.11 per share, with a total value of $197,074.37. Following the completion of the acquisition, the director now owns ...
4/23/2021 Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down Following Analyst Downgrade baseballnewssource.com ... nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $27.58. Get Syndax Pharmaceuticals alerts:In related news, Director Dennis Podlesak acquired 13,967 shares of the stock in a transaction on Thursday, April 22nd. The stock was purchased at an average price of $14.11 per share, for a total transaction of $197,074.37. Following the completion ...
4/23/2021 Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 7.1% After Insider Buying Activity American Banking News ... as $15.59 and last traded at $15.20. 2,705 shares were traded during trading, a decline of 100% from the average session volume of 836,824 shares. The stock had previously closed at $14.19.Specifically, Director Dennis Podlesak purchased 13,967 shares of the business’s stock in a transaction that occurred on Thursday, April 22nd. The shares were acquired at an average cost of $14.11 per share, for a total transaction of ...
7/22/2019 Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market Globe Newswire ... satisfied the requirements for listing of the Company’s shares on the OTCQB Market (OTCQB) and will begin trading on the OTCQB today. "We are very pleased to welcome Greg to the Adynxx board,” said Dennis Podlesak , Partner, Domain Associates and Adynxx’s Chairman. “He has an exceptional track record of building successful life science companies and getting novel drugs approved, and his operational and commercial expertise will be instrumental to Adynxx ...
7/22/2019 Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market Business Insider ... satisfied the requirements for listing of the Company’s shares on the OTCQB Market (OTCQB) and will begin trading on the OTCQB today. "We are very pleased to welcome Greg to the Adynxx board,” said Dennis Podlesak , Partner, Domain Associates and Adynxx’s Chairman. “He has an exceptional track record of building successful life science companies and getting novel drugs approved, and his operational and commercial expertise will be instrumental to Adynxx ...
5/6/2019 Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors Globe Newswire ... tremendous confidence in Rick and his team, especially given Rick’s outstanding track record of building successful biopharmaceutical companies that have brought multiple new drug products to market and delivered strong returns for shareholders,” said Dennis Podlesak , Partner, Domain Associates and Adynxx’s Chairman. “Today we are also pleased to announce the addition to the board of Pierre Legault and Matt Ruth, two accomplished pharmaceutical industry leaders. Their guidance and expertise will ...
5/6/2019 Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors Globe Newswire ... tremendous confidence in Rick and his team, especially given Rick’s outstanding track record of building successful biopharmaceutical companies that have brought multiple new drug products to market and delivered strong returns for shareholders,” said Dennis Podlesak , Partner, Domain Associates and Adynxx’s Chairman. “Today we are also pleased to announce the addition to the board of Pierre Legault and Matt Ruth, two accomplished pharmaceutical industry leaders. Their guidance and expertise will ...